Food and Feed Immunology Group, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan.
BMC Immunol. 2013 Aug 15;14:40. doi: 10.1186/1471-2172-14-40.
Some studies have shown that nasally administered immunobiotics had the potential to improve the outcome of influenza virus infection. However, the capacity of immunobiotics to improve protection against respiratory syncytial virus (RSV) infection was not investigated before.
The aims of this study were: a) to evaluate whether the nasal administration of Lactobacillus rhamnosus CRL1505 (Lr05) and L. rhamnosus CRL1506 (Lr06) are able to improve respiratory antiviral defenses and beneficially modulate the immune response triggered by TLR3/RIG-I activation; b) to investigate whether viability of Lr05 or Lr06 is indispensable to modulate respiratory immunity and; c) to evaluate the capacity of Lr05 and Lr06 to improve the resistance of infant mice against RSV infection.
Nasally administered Lr05 and Lr06 differentially modulated the TLR3/RIG-I-triggered antiviral respiratory immune response. Lr06 administration significantly modulated the production of IFN-α, IFN-β and IL-6 in the response to poly(I:C) challenge, while nasal priming with Lr05 was more effective to improve levels of IFN-γ and IL-10. Both viable Lr05 and Lr06 strains increased the resistance of infant mice to RSV infection while only heat-killed Lr05 showed a protective effect similar to those observed with viable strains.
The present work demonstrated that nasal administration of immunobiotics is able to beneficially modulate the immune response triggered by TLR3/RIG-I activation in the respiratory tract and to increase the resistance of mice to the challenge with RSV. Comparative studies using two Lactobacillus rhamnosus strains of the same origin and with similar technological properties showed that each strain has an specific immunoregulatory effect in the respiratory tract and that they differentially modulate the immune response after poly(I:C) or RSV challenges, conferring different degree of protection and using distinct immune mechanisms. We also demonstrated in this work that it is possible to beneficially modulate the respiratory defenses against RSV by using heat-killed immunobiotics.
一些研究表明，鼻腔内给予免疫生物制剂有可能改善流感病毒感染的结局。然而，免疫生物制剂改善呼吸道合胞病毒（RSV）感染保护的能力在此前并未得到研究。
本研究的目的为：a）评估是否鼻腔给予鼠李糖乳杆菌 CRL1505（Lr05）和 L. rhamnosus CRL1506（Lr06）能够改善呼吸道抗病毒防御并有益地调节 TLR3/RIG-I 激活引发的免疫反应；b）研究 Lr05 或 Lr06 的活力是否对调节呼吸道免疫必不可少；c）评估 Lr05 和 Lr06 改善婴儿小鼠抵抗 RSV 感染的能力。
鼻腔内给予的 Lr05 和 Lr06 差异调节 TLR3/RIG-I 触发的抗病毒呼吸道免疫反应。Lr06 给药显著调节了对 poly(I:C) 挑战的 IFN-α、IFN-β 和 IL-6 的产生，而 Lr05 鼻腔给药对改善 IFN-γ 和 IL-10 水平更有效。两株活的 Lr05 和 Lr06 株均增加了婴儿小鼠对 RSV 感染的抵抗力，而仅热灭活的 Lr05 显示出与活株相似的保护作用。
本工作表明，鼻腔内给予免疫生物制剂能够有益地调节 TLR3/RIG-I 激活在呼吸道引发的免疫反应，并增加小鼠对 RSV 挑战的抵抗力。使用两种源自同一来源且具有相似技术特性的鼠李糖乳杆菌的比较研究表明，每种菌株在呼吸道具有特定的免疫调节作用，并且在 poly(I:C)或 RSV 挑战后它们差异调节免疫反应，赋予不同程度的保护并使用不同的免疫机制。我们还在本工作中证明，使用热灭活免疫生物制剂有可能有益地调节针对 RSV 的呼吸道防御。
